Incidence of Non-Hodgkin Lymphoma Among Breast Cancer Survivors: Nationwide Cohort Study

Overview

This nationwide Korean cohort study evaluated the incidence of non-Hodgkin lymphoma (NHL) among breast cancer survivors compared to matched controls. It found that breast cancer survivors had an increased risk of developing NHL, with variations according to treatment modalities and NHL subtypes.

Background

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy globally, with survival rates varying by stage and subtype. The etiology of NHL is heterogeneous and not fully understood, though immune suppression is a known risk factor for some subtypes. Prior studies suggested a possible association between breast cancer and increased NHL risk, but were limited by small sample sizes and lack of detailed treatment data. This study aimed to clarify the relationship using a large, nationwide cohort with detailed treatment and health screening information.

Data Highlights

Key Findings

• Breast cancer survivors had a statistically significant increased incidence of NHL compared to matched controls without breast cancer.
• The study included 84,969 breast cancer cases and 1,057,674 controls, all undergoing at least one health screening exam.
• Risk of NHL varied by breast cancer treatment type, with hormone therapy and combined modalities influencing NHL incidence.
• NHL subtypes analyzed included diffuse large B-cell lymphoma, follicular lymphoma, mature T/NK-cell lymphomas, and anaplastic large cell lymphoma.
• The use of a comprehensive national health insurance database allowed for reliable identification of cancer diagnoses and treatments.

Clinical Implications

Clinicians should be aware of the elevated risk of NHL among breast cancer survivors, particularly when selecting treatment modalities. Monitoring for hematologic malignancies may be warranted in long-term follow-up of breast cancer patients, especially those receiving hormone therapy or combined treatments. Understanding subtype-specific risks can guide personalized surveillance strategies.

Conclusion

This large-scale nationwide cohort study demonstrates an increased incidence of NHL among breast cancer survivors, highlighting the need for vigilance in monitoring secondary hematologic malignancies in this population. Further research is needed to elucidate the mechanisms linking breast cancer treatments and NHL risk.

References

1. Korean National Health Insurance Service Data -- Nationwide Cohort Analysis
2. Epidemiology and Survival Rates of NHL -- Global Cancer Statistics